Watchlist Price Alert

Heron Therapeutics Inc. (HRTX)

NASDAQ: HRTX · Real-Time Price · USD

2.10

-0.07 (-3.23%)

At close: May 09, 2025, 3:59 PM

2.12

0.71%

After-hours: May 09, 2025, 05:52 PM EDT

-3.23% (1D)

Bid	2.08
Market Cap	321.15M
Revenue (ttm)	153.74M
Net Income (ttm)	-13.58M
EPS (ttm)	-0.09
PE Ratio (ttm)	-23.39
Forward PE	42.1
Analyst	Buy

Ask	2.34
Volume	1,580,772
Avg. Volume (20D)	1,902,972
Open	2.17
Previous Close	2.17
Day's Range	2.10 - 2.25
52-Week Range	1.04 - 3.93
Beta	1.33

About HRTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol HRTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for HRTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Heron Therapeutics has released their quartely earnings on May 6, 2025:

Revenue of $38.9M exceeds estimates by $1.48M, with 12.21% YoY growth.

EPS of 0.01 exceeds estimates by 0.02, with 150.00% YoY growth.

Why Price Moved

5 days ago

+13.62%

Heron Therapeutics shares are trading higher after... Unlock content with Pro Subscription

2 months ago

+20.49%

Heron Therapeutics shares are trading higher following better-than-expected Q4 financial results.

News

4 days ago · seekingalpha.com

Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025

HRTX's Q1'25 earnings highlight Cinvanti as the top earner, but Zynrelef shows strong growth potential, with 60% growth in net sales vs Q1'24. HRTX reported net income of $2.6M and raised its full-yea...

6 days ago · seekingalpha.com

Heron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call Transcript

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Officer I...

5 days ago · zacks.com

Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metric...

5 days ago · zacks.com

Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates

Heron Therapeutics (HRTX) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.02 per share a year ago.

1 week ago · zacks.com

Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

2 weeks ago · zacks.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

2 weeks ago · zacks.com

Best Momentum Stocks to Buy for April 22nd

DPMLF, HRTX and FOX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 22, 2025.

2 weeks ago · zacks.com

New Strong Buy Stocks for April 22nd

DPMLF, PAM, MTAL, HRTX and BALY have been added to the Zacks Rank #1 (Strong Buy) List on April 22, 2025.

2 months ago · seekingalpha.com

Heron Therapeutics, Inc. (HRTX) Q4 2024 Earnings Call Transcript

Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Melissa Jarel - Executive Director, Legal Craig Collard - Chief Executive Off...

Load More News